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Abstract
We present a full-length a1b2c2 GABA receptor model optimized for agonists and benzodiazepine (BZD) allosteric
modulators. We propose binding hypotheses for the agonists GABA, muscimol and THIP and for the allosteric modulator
diazepam (DZP). The receptor model is primarily based on the glutamate-gated chloride channel (GluCl) from C. elegans and
includes additional structural information from the prokaryotic ligand-gated ion channel ELIC in a few regions. Available
mutational data of the binding sites are well explained by the model and the proposed ligand binding poses. We suggest a
GABA binding mode similar to the binding mode of glutamate in the GluCl X-ray structure. Key interactions are predicted
with residues a1R66, b2T202, a1T129, b2E155, b2Y205 and the backbone of b2S156. Muscimol is predicted to bind similarly,
however, with minor differences rationalized with quantum mechanical energy calculations. Muscimol key interactions are
predicted to be a1R66, b2T202, a1T129, b2E155, b2Y205 and b2F200. Furthermore, we argue that a water molecule could
mediate further interactions between muscimol and the backbone of b2S156 and b2Y157. DZP is predicted to bind with
interactions comparable to those of the agonists in the orthosteric site. The carbonyl group of DZP is predicted to interact
with two threonines a1T206 and c2T142, similar to the acidic moiety of GABA. The chlorine atom of DZP is placed near the
important a1H101 and the N-methyl group near a1Y159, a1T206, and a1Y209. We present a binding mode of DZP in which
the pending phenyl moiety of DZP is buried in the binding pocket and thus shielded from solvent exposure. Our full length
GABAA receptor is made available as Model S1.
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Introduction
c-aminobutyric acid (GABA) is the major inhibitory neuro-
transmitter in the central nervous system (CNS) as opposed to
glutamic acid, which is the primary excitatory CNS-neurotrans-
mitter (Figure 1). Structurally, the two compounds are similar, and
in fact GABA is formed in vivo by decarboxylation of glutamate.
GABAA receptors (GABAARs) are involved in a number of
important functions such as cognition, learning, and memory and
in disorders such as epilepsy, anxiety, schizophrenia, sleep
disorders, and depression [1]. The GABAARs belong to the Cys-
Loop receptor family that also includes nicotinic acetylcholine
receptors (nAChRs), serotonine type 3 receptors (5-HT3Rs) and
glycine receptors (GlyRs). All Cys-Loop receptors are homomeric
or heteromeric assemblies of five subunits forming a central ion-
conducting pore (Figure 2). The GABAARs and GlyRs conduct
anions whereas nAChRs and 5-HT3Rs are cation selective. Each
subunit is made up of an extracellular domain (ECD) consisting of
mainly b-sheets, and a trans-membrane domain (TMD) consisting
of four membrane spanning a-helices. GABAAR subunits include
a1–6, b1–3, c1–3, d, e, p, h, r1–3 and the most abundant GABAAR
subunit combination in the human CNS is the a1b2c2 subtype
where the endogenous neurotransmitter GABA binds in each of
the interfaces between b2 and a1 subunits (Figure 2). A modulatory
site for benzodiazepine (BZD) like compounds is found in a
homologous position between a1 and c2 subunits.
Despite decades of research and a wealth of experimental and
theoretical studies, the exact binding mode of key agonists
including GABA is still unknown. The same is the case for the
BZDs. Key agonists for the GABA binding site include the high
affinity agonist muscimol [2,3] and the partial agonist THIP [4,5],
which is a structurally restrained muscimol analog (Figure 1).
THIP was long in clinical trials for treatment of insomnia, but was
discontinued. Still, the GABAAR agonist binding site is regarded a
promising drug target and represents an intriguing alternative to
the BZD binding site, which has long been the target for allosteric
modulators including BZDs such as diazepam (Figure 1). BZDs
are still one of the most prescribed classes of drugs for the
treatment of insomnia, anxiety, and convulsions [6,7].
So far, drug discovery efforts have relied mainly on indirect
structural insight from focused [8–12] or unified pharmacophore
models recapitulating the structure-activity relationships (SAR) of
compounds synthesized during more than fifty years of active
medicinal chemistry research in the field [13,14]. Homology
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models, on the other hand, have had little practical impact on the
design process despite a number of models reported in the
literature [15–25]. The models were mainly built using the
homologous acetylcholine binding proteins (AChBPs) as templates.
The AChBPs have supplied insight into a number of structural
features of Cys-Loop receptors. The position of loops A–F
(Figure 2) known from mutational studies to participate in ligand
binding were established with the first AChBP structure [26]. A
high degree of flexibility has later on been observed for the C-loop,
which is a hair-pin shaped loop that embraces the orthosteric
binding sites and shields from the solvent [27]. It was observed that
depending on the type of ligand in the binding site, the C-loop
either exists in a closed (agonist) conformation or an open
(antagonist) conformation allowing large inhibitors to enter the
binding site. This C-loop movement has also been speculated to be
linked to the activation mechanism of Cys-Loop receptors [28].
Although, the AChBPs have proven valuable templates for
modeling of nAChRs [26,29–32] they suffer from a lack of
conservation of binding site residues with respect to GABAARs,
which makes them unsuitable as stand-alone templates for
GABAAR homology modeling. To compensate for the lack of
conservation of binding site residues, we have recently reported a
novel strategy for GABAAR modeling utilizing experimental
restraints and multiple templates including AChBPs from different
species [27,33], a mouse a1 nAChR subunit [34], and the bacterial
orthologs from Gloeobacter violaceus (GLIC) [35] and Erwinia
chrysanthemii (ELIC) [36] in the alignment generation and model
building steps [37]. In particular, inclusion of the ELIC structure
adds important conserved binding site residues to the pool of
template structures. Using this strategy, a reliable model of the
GABAAR ECD with focus on the orthosteric ligand binding
interface of the a1b2c2 GABAAR in its non-activated (antagonized)
state was obtained. The model was consistent with experimental
data and capable of rationalizing the structure activity relation-
ships (SAR) of a series of GABAAR orthosteric antagonists [37].
With the recent release of atomic resolution structures of a
eukaryotic glutamate gated chloride channel (GluCl) [38] from the
nematode C. elegans, the molecular basis for modeling of
pentameric ligand gated anion channels has improved consider-
ably. The GluCl structure has an unprecedented high sequence
identity compared to the GABAAR; 30%, 36%, and 31% relating
to a1, b2 and c2 subunits, respectively, and even higher identities
Figure 1. Some classical GABAA receptor ligands. GABA is the
endogenous GABAR agonist, muscimol a classical high-affinity agonist
and THIP a muscimol analogue. Although not a GABAR ligand,
glutamate is included to illustrate the resemblance to GABA. Diazepam
(DZP) belongs to the benzodiazepine class of compounds, which are
allosteric GABAA modulators. The DZP-NCS analogue attaches cova-
lently to GABAARs and is included for validation purposes.
doi:10.1371/journal.pone.0052323.g001
Figure 2. Illustration of the GABAAR structural composition. A) Top view showing the pentameric assembly of a1, b2 and c2 subunits and the
location of binding sites for GABA and BZDs; B) Side view illustrating the extracellular domain (ECD) where agonists and benzodiazepines bind and
the transmembrane domain (TMD); C) Zooming in on a GABA binding site at the subunit interface between b2 and a1 subunits, loop regions A–F
mentioned in the text are shown (A: yellow, B: orange, C: red, D: purple, E: blue and F: pink).
doi:10.1371/journal.pone.0052323.g002
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with respect to the ligand binding cores (,48% in an 8 A˚ radius
from glutamate in GluCl). The GluCl structure was crystallized in
presence of its agonist glutamate and was captured in its presumed
open state.
In this report we demonstrate the use of the GluCl structure as
template for construction of a GABAA receptor homology model
comprising both the ECD and TMD portions of the receptor. We
show that when combined with the structure of the bacterial ELIC
channel, a reliable GABAAR model based entirely on full length
receptor X-ray structures can be obtained. The model is built in
the open state with GABA in the two orthosteric binding sites
between b2 and a1 subunits. The BZD binding site between the a1
and c2 subunit is adapted to the positive allosteric modulator
diazepam (DZP). The model is capable of explaining SARs,
mutational data, and data from studies of covalent linking of a
DZP-derivative to cysteine mutants of the receptor. Therefore, the
validated model might also serve as a tool for structure guided
design of new agonists and allosteric modulators and may form the
link to interpretation of previously reported pharmacophore
models [11,14,39] in a structural context.
Methods
Homology modeling
Templates, sequences and sequence alignment. The X-
ray structure of GluCl co-crystallised with glutamate (PDB code
3RIF) [38] was used as primary template for homology modeling
of the most abundant subtype of the GABAAR, a1b2c2. In a few
important regions with low sequence identity to GluCl the
bacterial homologue ELIC (PDB code 2VL0) [40], which has a
20% sequence identity to GluCl, was included as template as well.
The extent to which each template structure was used is specified
in Figure 3, in which the definitions for the general secondary
structural elements of Cys-Loop receptors referred to throughout
this paper are also indicated. The rationale for including ELIC as
template in the areas highlighted in Figure 3 were the following: 1)
In the b1 and b2 sheets the ELIC structure contains aromatic
residues in positions 19 and 38 resembling those in the GABAAR;
2) In the b6–b7-loop (Cys-Loop) and in the b7 and b10 strands
ELIC was included as template for the b2 subunit to capture
information about the conformations of and interactions between
GABAAR b2E155 and b2R207; 3) In the M2–M3-loop ELIC was
included as template due to the presence of Pro residues in
homologous positions.
The sequence alignment was obtained following the procedure
reported by Sander et al. [37] First, a structural alignment of the two
template structures was generated using Pymol 1.3 [41]. Subse-
quently, all human GlyR a-subunits and all human GABAAR
subunits were aligned to the GluCl sequence as profile alignments
with iteration on the last alignment using ClustalX v. 2.0.12 [42].
The GlyR a-subunits represent the closest human homologs to
GluCl and were included to aid identification of semi-conserved
motifs. In three regions, namely, 1) in and after the N-terminal a-
helix, 2) in loop F, and 3) in loop C, manual adjustments of the
generated alignment were performed to ensure proper alignment
of conserved motifs. 1) In the N-terminal a-helix the motif
represented by the GABAA a1 sequence ILDRLLDGYDNRLRP
was misaligned by ClustalX due to the presence of insertions in the
GlyR a-subunit sequences and the GABAAR r-subunit sequences.
Therefore, this motif was reestablished as described by Sander et
al. [37] 2) In loop F varying sequence lengths and low sequence
identity resulted in a poor alignment and many gaps. We identified
a hydrophobic-X-hydrophobic motif (corresponding to VVV in
the GABAAR a1-subunit), forming a short b-strand of three
residues in GluCl, ELIC, the bacterial ion channel GLIC (PDB
ID: 3EAM) the mouse nAChR a1-subunit (PDB ID: 2QC1) and in
AChBPs from Aplysia californica (PDB ID: 2BYQ) and Bulinus
truncatus (PDB ID: 2BJ0) [27,34,35,43]. The generated alignment
was manually adjusted to re-establish this motif in the GABAAR
sequences. 3) In loop C, the automatically generated alignment
from ClustalX had gaps in the GABAAR sequences in the b-sheet
regions. These were manually moved to the tip of the loop as it is
generally accepted that the length of loop C varies between
families and subtypes of Cys-Loop receptors. 4) Finally, we
truncated the M3–M4 intracellular loop and inserted an AGT
tripeptide according to the GluCl structure. The manually
adjusted alignment is reported in Figure 3.
Prior to model building the GluCl X-ray structure was prepared
as follows. The FAB fragments (chains F–O) as well as all
heteroatoms were removed except glutamates in the orthosteric
binding sites between chains A, B and C, D. Then the a-carboxylic
acid moiety was deleted from the glutamate ligands, resulting in a
GluCl template structure with GABA in the two orthosteric
binding sites between chains A, B and C, D.
Model building, evaluation and selection. The program
MODELLER 9v7 [44] was used for homology modeling using the
‘‘automodel class’’, which includes no other restraints than spatial
restraints gathered from the sequence alignment. 100 models were
generated, and the refinement level ‘‘refine.slow’’ was applied.
GABA molecules were modeled into the two b2-a1 subunit
interfaces in the GABAA receptor model as rigid bodies.
The final model selection was performed according to the
consensus scoring approach described by Sander et al. [37] using
the ProSA z-score [45], the energy according to the OPLS 2001
force field [46,47] as implemented in Maestro [48], and the
MODELLER built in scoring functions, molpdf and DOPE score
[44]. The consensus 10 best scoring models were assessed visually
for physico-chemical requirements such as packing of hydrophobic
residues in hydrophobic environments and solvent exposure of
charged residues. Also, the interactions between the modeled
GABA molecule and the receptor model were assessed as part of
the selection criteria.
Model refinement
The selected model was subjected to the protein preparation
wizard in Maestro [48], which adds hydrogen atoms, assigns bond
orders, creates disulphide bonds and samples hydrogen bond
networks. Furthermore, the protein preparation wizard assesses
the protonation state of His, Lys, Arg, Glu, and Asp. As is seen in
the GluCl structure E293 interacts with R245 and D316,
indicating that this residue exists in its protonated form. Therefore,
the corresponding five Glu residues (two a1E302, two b2E298, and
one c2E313) in the homology model, which also coordinates to
Arg and Asp were protonated. The protein preparation wizard
and the PROPKA web server [49–51] further supported this
assessment. All other residues were kept at their standard
protonation states (neutral His, protonated Lys and Arg and
deprotonated Glu and Asp). Finally, an energy minimization with
a flat-bottomed Cartesian constraint and a convergence threshold
set to an RMSD of 0.3 A˚ was performed.
The model was further refined as follows: 1) The rotameric state
of a1R66 (in chain D) was optimized for optimal bidentate
interactions with GABA using the side chain refinement tool in
Prime [52]; 2) Hydrogen bond networks between the GABA
molecules and the receptor model were manually optimized by
selecting appropriate rotamers of a1T129 similar to the homol-
ogous S121 in the GluCl structure; 3) Loop A (residues 99–102) in
the BZD site carrying a1H101 was sampled using the loop
A Unified Model of the GABAA Receptor
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sampling protocol in Prime [52] in order to obtain an orientation
of a1Asn102 in agreement with the template structure; 4) A
rotamer of b2K196 able to make a salt bridge with b2E153 was
selected (Table 1).
Ligand docking and binding site characterization
GABA, muscimol, and THIP were created in their ionized
states in Maestro 9.2 [53] followed by conformational searches
with MacroModel 9.9 (default settings) [54]. The global energy
minimum conformations were identified and used as input
conformations for docking. The agonists were docked into the
orthosteric binding site between chains A and B using the Glide
Induced Fit Docking (IFD) protocol [55,56] and the Extra
Precision (XP) scoring function [57]. By default the IFD procedure
allows amino acid side chains to adapt to the docked ligand in a
5 A˚ sphere. Docking poses were selected based on compliance
with mutational data (Table 1) and common interaction patterns
in the binding site. Finally, selected ligand poses including residues
in an 8 A˚ sphere were energy minimized to convergence using
MacroModel 9.9.
The program GRID [58,59] was used to characterize the non-
bonded water interaction properties of the vacant binding pocket
between chains A and B (GABA site) of the refined model using
the water probe (OH2). A grid spacing of 0.33 A˚ was used and all
other settings were kept at their default values.
Quantum mechanical (QM) calculations was performed using
Jaguar 7.8 [60]. For muscimol, a relaxed coordinate scan was
performed to determine conformational energies when varying the
amino-methyl side chain dihedral angle in a step size of 10u
between 0–180u. The Poisson-Bolzmann aqueous solvation model
Figure 3. Alignment of protein sequences from GluCl, GLIC, ELIC and the human a1, b2, and c2 GABAAR subunits. The GluCl sequence
was used as template for homology modeling throughout the GABAAR subunits, and ELIC was included as a template in the regions marked with
blue boxes. The secondary structure deduced from the X-ray structure of GluCl is shown above the alignment (red shapes denote a-helices, and
green arrows denote b-strands), whereas historically assigned loop regions are indicated below the alignment. As in the GluCl structure the M3–M4
intracellular loop of GABAAR sequences was replaced by an AGT tri-peptide linker. Residues comprising the binding sites (within 8 A˚ of Glu in the
GluCl structure and pointing towards the binding site) are colored pink (Glu and GABA binding site) and cyan (BZD binding site). Binding site residues
conserved with respect to the templates are indicated as follows: + conserved in both GABA and BZD binding sites; * conserved in the GABA binding
sites; . conserved in the BZD binding site. For details on calculation of binding site sequence identities see Figure S1.
doi:10.1371/journal.pone.0052323.g003
A Unified Model of the GABAA Receptor
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[61] and otherwise default settings were selected (B3LYP/6-
31G**). Gas-phase energies were extracted from the results in
order to consider only the steric energies.
The docking procedure described for the agonists was also
attempted for DZP at the BZD site, but none of the obtained poses
could be rationalized by experimental data. DZP was docked using
its assumed bioactive conformation as input for docking [62–66].
QM partial charges were calculated using Jaguar 7.6 default
settings. Subsequently, DZP was manually docked to the BZD
binding site according to experimental evidence: Docked DZP
should 1) have the Cl-substituent positioned in the vicinity of or
pointing towards a1H101, a1N102 [67], a1G157, a1V202, and
a1V211 [68], 2) have the C-3 atom positioned in the vicinity of or
directed towards a1S205 and a1T206 [69], 3) have the N-methyl
substituent directed towards an exit from the binding cavity [70],
and 4) have the pending phenyl ring positioned in a lipophilic
cavity [71,72]. Following manual positioning of DZP, the a1-c2
interface was allowed to adapt to DZP using the side chain
prediction tool in Prime in which backbone and residue sampling
within 4 A˚ of DZP was performed. As a final step, Prime performs
a minimization of the complex, the docked ligand and the
surrounding residues in question (backbone and side chains). The
protein and the ligand were thus allowed to adapt to each other.
The final model was further validated using 1) mutational studies
from the literature (Table 2), 2) in silico covalent docking of a Cys-
reactive DZP derivative, and 3) assessment of SAR data from the
literature in a structural context.
As a validation of the DZP binding mode, the Cys-reactive BZD
derivative DZP-NCS [67,68,73,74] (Figure 1) was covalently
docked to an a1H101C variant of the homology model using the
‘‘covalent docking’’ module in Prime. The covalent docking
module works by eliminating two atoms in order to form a new
bond between the reacting molecules/species. Since Prime cannot
handle simultaneous reduction of a double bond and formation of
a new bond, the isothiocyanato group of DZP-NCS was reduced
to a methanethioamide group prior to submission of the job. The
thiol-hydrogen was defined as the leaving receptor atom. The
conformation of the attachment residue was sampled and all other
residues were kept fixed.
Finally, a 48 ns molecular dynamics simulation was performed
to assess the stability of the final GABAAR model. Details are
supplied as Model S1.
Results and Discussion
With the improved structural templates available from efforts in
structural biology it is now possible to build a1b2c2 GABAAR
models based entirely on full length receptor templates. We have
created a full-length a1b2c2 GABA model mainly based on the
glutamate bound GluCl X-ray structure and partly using the
bacterial Cys-Loop homolog ELIC as an additional template. The
model has been optimized in the GABA and BZD binding sites for
the agonists GABA, muscimol and THIP and the modulator
diazepam. The GluCl X-ray structure with glutamate bound was
crystallized in an open state with a negatively charged ion in the
lower part of the TMD [38]. The ELIC structure, on the other
hand, was crystallized in a putatively closed state in absence of a
bound ligand [36]. Since only a few residue positions in our model
Table 1. Overview of mutations affecting the function of the GABAAR or the binding of orthosteric ligands.
Residue Proposed function/feature Reference(s)
Structural features
b2E153, b2K196 Intra-subunit salt bridges important for receptor function. [112]
Ligand-binding features
a1F64 Affects binding of bicuculline and gabazine and SCAM identified residue to be part of binding site. [84–86,113]
a1R66 Identified by SCAM to be part of binding site. [84,86]
a1L117 Identified by SCAM to be part of binding site. Also binding of gabazine is affected. [89]
a1R119 Predicted by SCAM to line binding site. Mutation to Lys results in 180 fold reduced EC50 for GABA
and inability of muscimol and gabazine to bind.
[89,114]
a1T129 Predicted by SCAM to line binding site. [85,89]
a1R131 Predicted by SCAM to line binding site. [89]
b2Y97 Identified by SCAM to be part of binding site. Artificial amino acid mutagenesis indicates
participation in pi-cation interaction.
[91,115]
b2E155 Cys mutation gives rise to spontaneously open channel. Predicted to be connected to gating
and ligand binding.
[76]
b2Y157 Mutagenesis to Cys, Asn, Phe, and Ser indicate that this residue must be aromatic. Artificial amino acid
mutagenesis does not indicate pi-cation interaction with this residue.
[76,81,91]
b2F200 Cys mutation significantly affects gabazine affinity as well as receptor activation. [82]
b2S201 Cys mutation affects gabazine affinity as well as receptor activation. [82]
b2T202 Ala and Cys mutations renders receptor essentially inactive. Ser mutation is accepted but
decreases EC50 slightly.
[81,82]
b2G203 Cys mutation severely affects affinity of gabazine and activation of the recptor. [82]
b2Y205 Crucial residue that must be aromatic. Mutations to Ser and Asn renders the receptor
inactive, and mutation to Cys affects both gabazine binding and receptor
activation very severely.
[81,82]
b2R207 Affects GABA binding and un-binding rates. Predicted to be part of binding site. [78,82]
All data in the table are in agreement with our GABAAR model.
doi:10.1371/journal.pone.0052323.t001
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have been modeled based on the ELIC structure, the overall
architecture of the a1b2c2 GABA model is obtained from the
GluCl structure. Therefore, we regard our model as being in the
open state.
Model assessment
The pentameric GABAAR a1b2c2 ECD-TMD homology model
comprised 1676 residues distributed with 335, 334, and 333
residues in a1, b2, and c2 GABAAR subunits respectively. The
selected model had good backbone geometry with 98.8% of the
residues in favorable or additionally allowed regions in the
Procheck v. 3.5.4 Ramachandran plot [75]. All residues in
disallowed regions in the Ramachandran plot were situated in
solvent exposed loop regions distant to the binding site. The
ProSA z-scores for the selected homology model were within the
accepted area for X-ray structures from the PDB. Furthermore,
stability of the model was assessed by a 48 ns molecular dynamics
calculation which showed essentially no drift after termination of
the equilibration protocol (see Figure S2).
Validation by mutational data. Both the GABA and BZD
binding sites have been heavily investigated by site-directed
mutagenesis (Tables 1 and 2). Among these mutations, some have
been used to suggest which residues line the binding sites, which
residues interact directly with different ligands, and which are
regarded as important structural features of the receptor. These
experimental data, including those listed in Tables 1 and 2 that
were not directly imposed during model refinement, are explain-
able by our homology model with the suggested poses of GABA
and DZP as described below.
Agonist binding model
GABA. The X-ray structure of GluCl with glutamate bound
presents a good indication of how GABA would bind to the GABA
receptors. Our a1b2c2 GABA model confirms that a similar
GABA binding mode interacts well with the receptor and is in
agreement with the experimental mutational data presented in
Table 1. In this binding mode GABA forms salt bridges with
a1R66 and b2E155 and hydrogen bonds with a1T129, b2T202,
and the backbone of b2S156. Finally, there is a p-cation
interaction with b2Y205. The GABA binding mode from our
docking study is illustrated in Figure 5A. As described in the
methods section GABA was modeled into the binding pockets of
our receptor model as rigid bodies, which allowed space for GABA
in the binding site. However, hydrogen bonding network was not
optimized in the modeling process, hence, a few side chains
needed adjustments as described in the methods section.
The GABAA orthosteric binding site apparently resembles the
GluCl glutamate binding site to a large extent. However, there are
Table 2. Overview of mutations affecting the function of the GABAAR or the ability of BZD binding site ligands to bind to the BZD
binding site.
Residue Proposed function/feature Reference(s)
Ligand-binding features
a1F99 May be involved in p-p stacking or might in some other way interact
directly with ligands of the BZD type.
[67,96]
a1H101 May be involved in p-p stacking or might in some other way interact
directly with ligands of the BZD type.
[73,97,116]
a1Y159 Mutation to Ala, Cys or Ser severely affects binding affinity of BZDs. Residue
lines the binding site.
[67,68,98]
a1G200 This residue lines a distal part of the binding site [96,104,105,116]
a1V202 This residue lines a distal part of the binding site [96,104]
a1T206 Mutation to Ala, Val, and Cys severely affects binding affinity of BZD-site ligands. [68,69,99,102,105]
a1G207 Mutation to Cys severely affects binding affinity of flunitrazepam. [68]
a1Y209 Aromatic functionality of the residue at this position is required for high-affinity
binding of BZD binding site ligands.
[96,98,99]
c2F77 Aromatic functionality of the residue at this position is required for high-affinity
binding of BZD binding site ligands.
[100–102]
c2M130 This residue lines the binding site [96,102]
Covalently modified mutants
a1G157 7-NCS-derivatives of imidazo-BZDs react covalently with Cys-mutants of this residue
suggesting the 7-position of imidazo-BZDs points towards this residue.
[68]
a1Y159 The NCS-derivative of imidazo-BZD does not react covalently with Cys-mutants of this
residue. 7-substituent is not directed towards this residue.
[68]
a1V202 7-NCS-derivatives of imidazo-BZDs react covalently with Cys-mutants of this suggesting
the 7-position of imidazo-BZDs points towards this residue.
[68]
a1S205 The 3-NCS-derivative of flunitrazepam reacts covalently with the Cys-mutant, forming a
constitutively positively modulated receptor.
[69]
a1S206 The 3-NCS-derivative of flunitrazepam reacts covalently with the Cys-mutant, forming a
constitutively positively modulated receptor.
[69]
a1V211 7-NCS-derivatives of imidazo-BZDs react covalently with Cys-mutants of this residue
suggesting the 7-position of imidazo-BZDs points towards this residue.
[68]
All data in the table is in agreement with our GABAAR model.
doi:10.1371/journal.pone.0052323.t002
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a few crucial differences. Newell et al. [76] identified b2E155 to be
vital for GABAA ligand binding and channel gating. This residue is
lacking in the GluCl receptor, but is present in ELIC (Figure 4A), a
receptor, which is known to be activated by e.g. GABA [77], an
important reason for including the ELIC structure as modeling
template. The position of b2E155 in our receptor model is in
perfect hydrogen bonding distance to the protonated amine of
GABA, thereby forming a salt bridge deeply buried in the pocket
and surrounded by a number of aromatic residues (so-called
aromatic box). b2E155 is flanked by b2R207 intruding from
outside the pocket. This residue has also been investigated
experimentally and shown to affect GABA binding and un-
binding [78], which makes sense if GABA binds as predicted here,
since there is a clear electrostatic interaction between b2R207 and
GABA through b2E155. Two other important residues that are
non-conserved between GluCl and GABAA, but present in ELIC,
are the b2F200 (C-loop) and a1F64 (D-loop). They serve as
components of the aromatic box, taking part in shielding the
positive charge in an enclosure of aromatic planes.
When GABA was re-docked into the binding site, a similar
binding pose was identified (Figure 5A). This extended confor-
mation of GABA has previously been determined by X-ray
crystallography [79,80] and by conformational search found as
one of several low energy conformations. However, the GABA
alkyl chain is quite flexible, and it is likely that it is not entirely
fixed in the protein bound state. The distance between the two
charges is approximately 5 A˚ in the identified pose. However, even
if the GABA alkyl chain should be slightly bent, resulting in a
shorter inter-charge distance, optimal interactions can be obtained
in the binding pocket by GABA interacting with the backbone
carbonyl of b2Y157 in place of b2S156. Indeed, previous
pharmacophore models disagree on which should be the exact
charge-charge distance in GABAA agonists. However, it has
generally been proposed to be in the range 4–5 A˚ [11] and in fact,
our GABAAR model predicts that agonist with different inter-
charge distances (4–5 A˚) may bind equally well to the receptor.
Apart from the salt bridge to b2E155, the positive charge of GABA
is further surrounded by the aromatic ring of b2Y205 and makes a
hydrogen bond to the backbone b2S156 (B-loop) similar to
glutamate in the GluCl template structure. Mutational data show
that b2Y205 is crucial for binding gabazine, a selective,
competitive GABAA antagonist, and for channel gating and that
this residue must be aromatic for the receptor to be functional
(Table 1) [81–83]. The carboxylic acid of GABA is fixed between
b2 and a1 subunits by a bidentate interaction with a1R66 and
hydrogen bonds with the two threonines b2T202 (C-loop) and
a1T129. Again, these interactions make perfect sense in the light of
published experimental data (Table 1). Mutations of a1T202 have
a crucial impact on GABA activation of the GABAA receptor.
Mutation to Ala or Cys renders the receptor virtually inactive,
while some function is retained with a a1T202S mutation [81,82].
a1R66C mutations have shown a 300–500 fold decrease in EC50
and the residue was shown by the substituted cysteine accessibility
method (SCAM) to be part of the binding pocket [84,85]. This
residue has long been suspected to interact with the carboxylic
acid of GABA [84,86–88]. However, a1R119 (in GABAr1),
a1R131 and b2R207 have also been hypothesized to perform this
interaction [78,87,89]. Based on the GluCl X-ray structure and
available mutational data, the evidence for a1R66 to be the
arginine interacting with the GABA carboxylic acid is quite strong.
b2R207 interacts with GABA through b2E155 as discussed above.
In our model a1R119 (conserved in GluCl) has an important
structural role, as it links the a-subunit to the C-loop of the b-
subunit (hydrogen bond to the backbone of b2T202) thereby
forming a ‘‘roof’’ on top of the agonist binding site as well as an
enforced closed state of the C-loop. A closed C-loop has long been
regarded necessary for obtaining the active state of Cys-Loop
receptors [27,43,90]. a1R131 is found lining the back wall of the
binding site behind a1F64, where it interacts with a1D62 and the
backbone of b2D101. Nevertheless, the flexible a1R131 could also
reach b2Y97 to form a p-cation interaction. This residue was
identified by Padgett et al. [91] to participate in a p-cation
interaction in the GABAA receptors and they suggested that the
cation should originate from the GABA molecule. However, based
on our model a p-cation interaction between GABA and b2Y97 is
unlikely. Indeed, it has generally caused difficulty to generate a
Figure 4. Conserved template residues. The figure shows residues that are conserved or homologous to GABAAR binding site residues from the
GluCl X-ray structure (PBD ID 3RIF) as grey sticks and the bacterial Cys-Loop receptor homolog, ELIC (PDB ID 2VL0) as purple sticks. Glutamate as co-
crystallized with GluCl is shown in yellow, where the structure corresponding to GABA is shown as sticks and the a-carboxylic acid removed prior to
homology modeling is shown as lines. A) GABA binding site and B) BZD binding site.
doi:10.1371/journal.pone.0052323.g004
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GABAA receptor model with the aromatic ring of b2Y97 facing
the binding pocket, which has not changed with the improved
template GluCl [37,91]. The authors suggested a1R131 as an
alternative cation source in the binding site, and this would fit our
model. The mutational consequences of b2Y97C and a1R131C
could instead originate from perturbation of the activation
mechanism.
THIP and muscimol. The docked poses of the other
hallmark agonists THIP and muscimol are illustrated in
Figure 5B–C. Poses with similar interactions as described above
for GABA were identified, however, with some differences as
discussed below.
The rigid THIP is able to make the same interactions as GABA.
The 3-hydroxy-isoxazole moiety, a bio-isostere of the carboxylic
acid in GABA, interacts with a1R66, b2T202 and a1T129 similar
to GABA. Furthermore, the protonated amine forms a salt bridge
to b2E155 and a pi-cation interaction with the important b2Y205.
The pose obtained for muscimol at first seemed erroneous, due
to a slight displacement of the charged amine compared to GABA
and THIP (Figure 5C). In this pose the positive charge is tucked in
between the two C-loop aromatic residues b2Y205 and b2F200,
however, the salt bridge to b2E155 is retained. The acidic moiety
of the 3-hydroxy-isoxazole was perfectly placed similar to THIP
and GABA. Therefore, the only difference compared to the
GABA receptor interactions is a p-cation interaction with b2F200
instead of a backbone interaction to the B-loop. Despite numerous
docking attempts and efforts to manually reposition muscimol to a
pose similar to GABA and THIP, when energy minimized, the
muscimol amino-methyl side chain kept ‘‘flipping’’ back. A
dihedral drive using QM calculations revealed that the reason
was a preferred torsional angle (O-C-C-N) of the muscimol amino-
methyl side chain at ca. 45u (Figure 6). If both charges of muscimol
were to overlay with the charges of GABA in the bound state, it
would result in a torsional angle of $90u which would result in a
conformational energy penalty of $3 kcal/mol (Figure 6). Such a
high conformational energy is unlikely for a high affinity ligand as
muscimol (Ki = 6 nM), which binds to GABAA receptors with an
even higher affinity than GABA itself (Ki = 18 nM) [92,93]. The
identified binding mode of muscimol depicted in Figure 5C has an
O-C-C-N torsional angle of ca. 60u, which corresponds to a
conformational energy penalty of ,0.6 kcal/mol. Still, we were
puzzled if no interaction with a B-loop backbone carbonyl should
take place when muscimol binds. This is a generally accepted
binding feature of Cys-Loop receptor agonists [26,27,94]. A
GRID interaction energy calculation using the water probe (OH2)
prior to optimization of the orthosteric receptor pocket revealed a
region of high specificity for a water molecule (,211 kcal/mol)
next to the B-loop backbone carbonyls from b2S156 and b2Y157
(Figure 7A). When placing muscimol and a water molecule in the
orthosteric binding site, it was found that hydrogen bonding
distances were optimal and allowed muscimol a more extensive
bonding pattern within the binding site than GABA. When also
including the GABA binding pose, it was apparent that the GABA
positive charge and the water molecule occupy the same region in
the pocket (Figure 7B). We therefore propose that muscimol binds
in concert with a water molecule as illustrated in Figure 7A
resulting in a low conformational energy penalty and optimal
interactions with the GABAA orthosteric binding pocket.
BZD binding model
As described in the methods section DZP was manually
positioned in a binding mode (Figure 8) satisfying the listed
Figure 5. Agonist binding modes determined by induced fit docking. A) GABA (green), B) THIP (pink) and C) muscimol (cyan) are shown in
the orthosteric binding site at the interface between the b2 subunit (teal) and the a1 subunit (smudge).
doi:10.1371/journal.pone.0052323.g005
Figure 6. Conformational energy profile for dihedral drive of
the amino-methyl side chain of muscimol. B3LYP/6-31G**
energies.
doi:10.1371/journal.pone.0052323.g006
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criteria deduced from experimental literature data followed by
optimization of side chains in the binding pocket. The resulting
model agrees to a large extent with the binding mode of DZP,
recently described by Richter et al. [95] despite being built on
different templates and is further in agreement with available
mutational data (Table 2) indicating that residues a1F99, [67,96]
a1H101, [73,97] a1Y159, [96,98] a1Y209, [96,98,99] c2F77,
[100–102] and c2M130 [96,102] line the binding pocket. As was
the case for the GABA othosteric binding site, the GluCl template
contributes to the homology model with a higher similarity than
the previously available templates. Furthermore, the ELIC X-ray
structure adds information about a few BZD binding site residues
(c2Y58 and c2F77) lacking in the GluCl structure (Figure 4B). In
brief, the obtained binding mode of DZP orients the chlorine atom
of DZP towards a1H101 and positions it underneath the C-loop
pointing towards the base of the C-loop (Figure 8). The pending
phenyl ring is positioned in a narrow cavity between a1F99 (A-
loop), a1Y159 (B-loop), and c2F77 (D-loop) in the bottom of the
binding site shielded from solvent exposure. The carbonyl is
positioned in a manner similar to the carboxylic acid of GABA in
the orthosteric binding site. It links the two subunits at the
interface by hydrogen bonds to a1T206 (C-loop) and c2T142 (D-
loop). Finally, the polarized N-methyl group is situated near the C-
loop enabling polar contacts with a1T206, a1Y209 and the
backbone of a1Y159 (Figure 8).
BZD pharmacophore models based on SAR data have
predicted a lipophilic pharmacophoric feature (in the traditional
BZD pharmacophore terminology named L1) to be an essential
part of BZDs [71,103]. In DZP this feature corresponds to the
fused aromatic ring system, which in the model is buried beneath
the C-loop and shielded from solvent by the hydrophobic residues
a1V202, Cb of a1T206, a1Y209, and a1V211. a1V202 was
predicted by mutational studies to line the binding site [96,104]
and a1T206 and a1Y209 are both essential for ligand binding to
the BZD site [68,69,96,98,99,102,105]. SAR studies [71,103] state
that the pharmacophoric feature, L1, should be accommodated in
a narrow cavity that does not tolerate substitution at other
positions than that corresponding to C-7 in DZP (see Figure 1).
Our proposed DZP binding mode comply well with this notion,
since substitution at positions C-8 and C-9 would lead to steric
interference with backbone atoms of the C-loop. Substitution at
the C-6 position would lead to steric clashes with a1H101 and
c2F99 explaining why this is not tolerated. [71,72] However, the
cavity, in which the DZP C-7 substituent (pharmacophoric feature
L2), the chlorine atom, is positioned, has to be spacious enough to
accommodate larger substituents (e.g. a nitro group as seen in
flunitrazepam) [72]. This is indeed the case in our model. The
position of the pharmacophoric feature, L2, is further supported
by studies of covalent labeling of cysteine mutants [67,69]. In these
studies, a DZP derivative, where the chlorine atom is substituted to
a cysteine-reactive isothiocyanate group (DZP-NCS, Figure 1), is
covalently linked to cysteine mutants of the receptor. Covalent
labeling of a1H101C leads to a constitutively positively allosteri-
cally modulated receptor, which indicates that the ligand is
covalently attached in an orientation matching the orientation of
DZP in its bioactive conformation. We replicated this study in silico
through covalent docking of DZP-NCS and obtained a pose
complying with experimental data (Table 2) and resembling the
otherwise established binding mode (Figure 8B) among the top
scoring poses. As can be seen from the overlay of the docked DZP
and the covalently attached DZP-NCS, the two ligands obtain
similar binding modes, the primary difference being caused by a
slight rotation of the scaffold of DZP-NCS to allow for covalent
attachment of DZP-NCS. Furthermore, labeling of a1S205C,
a1T206C mutants by a C-3 DZP-NCS probe strongly indicates
the C-3 of DZP-NCS to point towards the tip of the C-loop [69].
Labeling with an imidazobenzodiazepine-NCS derivative of the
partial negative allosteric modulator Ro15-4513, further indicates
that C-7 should be oriented towards a1H101, a1N102, [67]
Figure 7. Region suited for a tightly bound water molecule identified in agonist site. A GRID calculation at the agonist binding site, using
the water probe, identified two regions of strong binding interaction energy (211 kcal/mol). One region is overlapping with the acidic moiety of
agonists and the other region is situated next to the backbone of b2S156 and b2Y157 (grey mesh). The calculation was performed in absence of
agonist in the binding site. In the picture, the site has been optimized for muscimol as described in the methods section. A) When a water molecule is
placed between muscimol and the B-loop backbone, perfect hydrogen bonding distances are obtained, resulting in optimal interactions between the
high affinity ligand muscimol and the GABA receptor. B) When also GABA is included in the site, it is obvious that the water molecule would make up
for the backbone interaction that GABA is predicted to make.
doi:10.1371/journal.pone.0052323.g007
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a1G157, a1V202, and a1V211, [68] also correlating with our
model.
Available SAR data for BZDs indicate that the pending phenyl
ring (pharmacophoric feature L3) is positioned in a narrow cavity
[71,72]. Substitution at the ring is only tolerated in the 29-position,
whereas substitution in positions 39 and 49 are poorly tolerated.
[71,72] Our model agrees with these observations, as the pending
phenyl ring is positioned in an aromatic box formed by a1F99,
a1H101, a1Y159, c2F99, and c2N128. In addition to satisfying
ligand requirements of aromatic burial, the described position of
the pending phenyl ring also serves as a strong contact point
between the a1 and the c2 subunits.
The remaining lipophilic pharmacophoric features L3 (corre-
sponding to the phenyl group in DZP) and LDI of the traditional
benzodiazepine pharmacophore models [14,71,103] are situated
near residues a1V202 and a1V211, and c2A79, c2L140, c2Y58,
c2Q56, respectively. The latter feature is not occupied by DZP but
is important for binding and function of other BZD binding site
ligands, e.g. indol-3-yl-glyoxylamides [106].
An additional point of inter subunit contact is the carbonyl
group of DZP. This carbonyl is positioned under the tip of the C-
loop and is in an optimal position to form hydrogen bonds across
the interface through a1T206 and c2T142, similar to how the
GABA carboxylate binds to b2T202 and a1T129 in the orthosteric
binding site. Indeed, mutation of a1T206 has been identified in
several studies to severely affect binding affinity of BZDs (Table 2).
Further interactions between DZP and the receptor model are
formed by the polarized N-methyl group. Due to the position of
the methyl group on a nitrogen atom, the hydrogen atoms are
more polarized than they would be if the methyl group was
attached to an aliphatic carbon, thereby being able to form polar
contacts with the receptor. This has been seen previously in
AChBP X-ray structures [94]. In our model these hydrogen atoms
are positioned in the negatively charged electrostatic field of the
backbone carbonyl oxygen of a1Y159 and the hydroxyl groups of
a1T206 and a1Y209. This also explains the beneficial effect of
including the N-methyl substituent in BZDs. [72]
Interestingly, when comparing the validated binding modes of
GABA and DZP in their respective binding sites it is intriguing to
see that corresponding residues, in particular b2T202/a1T206,
b2Y205/a1Y209, b2Y97/a1F99, b2Y157/a1Y159, a1T129/
c2T142 and a1F64/c2F77 are responsible for contacts between
receptor and ligands and that both GABA and DZP in a similar
manner bridge neighboring subunits. We have recently shown that
a third binding site exists in the a4a4 interface of the so-called low
sensitivity nAChR (a4)3(b2)2 and hypothesized that this could be
the nicotinic pendant of the BZD binding site [107]. The
structural model presented here may help to design experiments
to investigate this hypothesis and thus contribute to the ongoing
debate of the mechanism of action of BZDs [96,98,108–111].
Conclusions
The model and subsequent validation by available experimental
data shows that reliable GABAAR models can be obtained using
novel full length receptor templates. In addition to serving as a
model of how agonists and modulators may bind to the GABAAR,
the model may help to guide mutational studies unraveling the
mechanism by which agonists, BZDs and other allosteric
modulators work.
Compared to earlier templates used for homology modeling of
the GABAARs the emergence of the X-ray structure of the GluCl
ion channel has significantly increased the insight into the
architecture of anionic Cys-Loop receptors. With the new
templates, sequence identities with respect to GABA sequences
are as high as 36% and even up to 48% if narrowing the focus to
the agonist binding site. Hence, the information on side chain
conformations in the binding site of GABAAR/anion channels of
the Cys-Loop receptor family has now improved considerably.
Previously published homology models have mainly been modeled
with AChBP as template. With sequence identities as low as 19%
combined with the lack of a TMD as is the case when using
AChBPs as templates, homology models based on the GluCl
structure represents a big step forward.
Figure 8. DZP binding mode. A) The assumed biologically active binding mode of DZP (gray) at the interface between the a1 (smudge) and c2
(firebrick) subunits. In this conformation the C-3 points upwards and the pending phenyl substituent is directed inwards. B) Covalently attached DZP-
NCS (cyan) overlaid with DZP (gray). Only moderate differences between the docked and the covalently attached ligands exist.
doi:10.1371/journal.pone.0052323.g008
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Based on homology modeling, advanced docking methods, QM
calculations and a vast amount of collected experimental data, we
have identified binding hypotheses for GABA, muscimol, THIP
and diazepam and optimized the binding sites accordingly. Our
GABAAR model is modeled in the open state according to the
GluCl glutamate bound structure and is intended for creating
binding hypotheses of agonists or BZD site modulators. The model
is made available in Model S1.
Supporting Information
Model S1 The GABAAR model described in this paper.
(ZIP)
Figure S1 Calculations of binding site sequence identi-
ties.
(PDF)
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